Thursday 18 July 1 PM (Perth Time) - 3PM (Sydney Time)
https://grafa.com/channel/asx-paradigm-biopharmaceuticals
Paradigm Biopharma is continuing to progress the regulatory review of its novel treatment for conditions including osteoarthritis and Mucopolysaccharidosis. The company is developing an injectable iPPS treatment for diseases where inflammation plays a major pathogenic role. The late stage drug development company is working towards a Phase 3 clinical trial of its iPPS treatment.
LiveStream: Paradigm Biopharma (ASX:PAR) pursuing FDA review
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.005(1.69%) |
Mkt cap ! $112.9M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 31.0¢ | 28.5¢ | $431.5K | 1.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21578 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |